Participation in phase 1 trials for patients with cancer

[...]the treatment-related death risk always remained below 1% in all periods and across all cancers, except pancreatic cancer. [...]the sample size of CTEP-sponsored phase 1 studies was usually lower than those of industry-sponsored studies, increasing the risk of bias due to sparse data. Because s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Lancet (British edition) Ročník 400; číslo 10351; s. 473 - 475
Hlavní autor: Italiano, Antoine
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 13.08.2022
Elsevier Limited
Témata:
Cancer
Cancer therapies
Clinical trials
Clinical Trials, Phase I as Topic
Cytotoxicity
Drugs
FDA approval
Hematology
Human subjects
Humans
Medical research
Neoplasms - therapy
Oncology
Pancreatic cancer
Participation
Patient Participation
Patients
Pharmaceutical industry
Response rates
Tumors
United States > US
ISSN:0140-6736, 1474-547X, 1474-547X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:[...]the treatment-related death risk always remained below 1% in all periods and across all cancers, except pancreatic cancer. [...]the sample size of CTEP-sponsored phase 1 studies was usually lower than those of industry-sponsored studies, increasing the risk of bias due to sparse data. Because several pharmaceutical companies made a commitment to provide access to deidentified patient-level data, future studies should focus on the trends in treatment-related deaths and response rates for patients enrolled in industry-sponsored phase 1 studies and on the variables associated with outcomes.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Commentary-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:0140-6736
1474-547X
1474-547X
DOI:10.1016/S0140-6736(22)01533-1